CANY
EPZM

Caxton Associates (New York)’s Epizyme, Inc EPZM Stock Holding History

Caxton Associates (New York)’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-99,409
Closed -$114K – 801
2022
Q1 		$114K Buy
99,409
+69,109
+228% +$113K 0.01% 471
2021
Q4 		$76K Buy
+30,300
New +$119K 0.01% 536

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caxton Associates (New York)'s EPZM Position: Q2 2022 in Review

Caxton Associates (New York) sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 99,409 shares — an estimated $114K sold.

Caxton Associates (New York) first reported a position in EPZM in Q4 2021 and held it in 2 quarters. The position peaked at $114K in Q1 2022. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

  • Caxton Associates (New York) reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 99,409 Epizyme, Inc shares in Q2 2022, an estimated $114K.
  • Caxton Associates (New York) first reported a position in Epizyme, Inc in Q4 2021 and held it in 2 quarters.
  • Caxton Associates (New York)'s Epizyme, Inc position peaked at $114K in Q1 2022.
  • 93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.